|
Debt (Details) (USD $)
|
12 Months Ended |
0 Months Ended |
1 Months Ended |
4 Months Ended |
12 Months Ended |
0 Months Ended |
1 Months Ended |
|
|
|
|
|
|
|
|
Dec. 31, 2013
|
Feb. 28, 2013
|
Feb. 28, 2013
|
Dec. 31, 2012
|
Dec. 31, 2014
|
Dec. 31, 2012
|
Jul. 02, 2013
|
Jun. 30, 2014
|
Apr. 19, 2013
|
Dec. 31, 2011
|
Jan. 31, 2012
|
Nov. 30, 2012
|
Sep. 30, 2012
|
May 29, 2013
|
Apr. 28, 2008
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred financing costs |
|
|
|
|
$ 100,000 |
|
|
|
|
|
|
|
|
|
|
| Series A preferred stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion of convertible promissory notes into Series A preferred stock (in shares) |
16,623,092 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued |
|
|
|
23,975,000 |
|
23,975,000 |
|
|
|
23,975,000 |
|
|
|
|
|
| Share price of preferred stock (in dollars per share) |
|
|
|
|
|
|
|
|
$ 1.00 |
|
|
|
|
|
|
| Number of shares of preferred stock converted into shares of common stock |
(57,598,092) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A-1 preferred stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion of convertible promissory notes into Series A preferred stock (in shares) |
6,750,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares of preferred stock converted into shares of common stock |
(6,750,000) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in dollars per share) |
|
|
|
|
$ 7.23 |
|
|
|
|
|
|
|
|
|
|
| Series A preferred stock warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable into stock (in shares) |
|
|
|
|
|
|
1,940,000 |
|
|
|
|
|
|
|
|
| Exercise price (in dollars per share) |
|
|
|
|
|
|
1.00 |
|
|
|
|
|
|
|
|
| 10% Convertible promissory notes | Series A preferred stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
15,700,000 |
15,700,000 |
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued interest |
|
900,000 |
900,000 |
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion of convertible promissory notes into Series A preferred stock (in shares) |
|
16,623,092 |
16,623,092 |
|
|
|
|
|
|
|
|
|
|
|
|
| Conversion price (in dollars per share) |
|
$ 1.00 |
$ 1.00 |
|
|
|
|
|
|
|
|
|
|
|
|
| Short term convertible notes issued January 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate (as a percent) |
|
|
|
|
|
|
|
|
|
|
10.00% |
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
|
|
6,000,000 |
|
|
|
|
| Short term convertible notes issued September and November 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate (as a percent) |
|
|
|
|
|
|
|
|
|
|
|
10.00% |
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
|
|
|
9,700,000 |
|
|
|
| Short term borrowings with related parties, net of debt discount |
|
|
|
|
|
|
|
|
|
|
|
9,400,000 |
|
|
|
| Short term convertible notes issued September and November 2012 | Series A preferred stock warrant | Series A preferred stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price of warrants |
|
|
|
9,700 |
|
|
|
|
|
|
|
|
|
|
|
| Short term convertible notes issued September and November 2012 | Series A preferred stock warrant | Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated fair value of warrants |
|
|
|
|
|
|
|
|
|
|
|
300,000 |
|
|
|
| Short term convertible notes issued September 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of beneficial conversion feature |
|
|
300,000 |
|
|
|
|
|
|
|
|
|
|
|
|
| Short term convertible notes issued September 2012 | Interest Expense. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of debt discount and beneficial conversion |
200,000 |
|
|
|
200,000 |
100,000 |
|
|
|
|
|
|
|
|
|
| Short term convertible notes issued September 2012 | Warrant | Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated fair value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
100,000 |
|
|
| Pfizer note |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate (as a percent) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.931% |
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000,000 |
| Outstanding principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
7,800,000 |
|
| Accrued interest during period |
300,000 |
|
|
|
|
600,000 |
|
|
|
|
|
|
|
|
|
| Pfizer note | Series A-1 preferred stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
6,750,000 |
|
| Share price of preferred stock (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.1560 |
|
| Number of shares of preferred stock converted into shares of common stock |
|
|
|
|
|
|
966,218 |
|
|
|
|
|
|
|
|
| Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum borrowing capacity |
|
|
|
|
20,000,000 |
|
|
|
|
|
|
|
|
|
|
| Percentage of final payment equal to amount drawn under the Credit Facility |
|
|
|
|
8.00% |
|
|
|
|
|
|
|
|
|
|
| Estimated future principal payments due under the Credit Facility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
638,000 |
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
1,604,000 |
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
1,709,000 |
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
1,049,000 |
|
|
|
|
|
|
|
|
|
|
| Total |
|
|
|
|
5,000,000 |
|
|
|
|
|
|
|
|
|
|
| Interest expense |
|
|
|
|
300,000 |
|
|
|
|
|
|
|
|
|
|
| Interest payments |
|
|
|
|
100,000 |
|
|
|
|
|
|
|
|
|
|
| Term A Loan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum borrowing capacity |
|
|
|
|
5,000,000 |
|
|
|
|
|
|
|
|
|
|
| Period of consecutive equal monthly installments of principal and interest |
|
|
|
|
36 months |
|
|
|
|
|
|
|
|
|
|
| Interest rate (as a percent) |
|
|
|
|
6.40% |
|
|
|
|
|
|
|
|
|
|
| Term A Loan | Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercisable into stock (in shares) |
|
|
|
|
|
|
|
8,230 |
|
|
|
|
|
|
|
| Exercise price (in dollars per share) |
|
|
|
|
|
|
|
$ 15.19 |
|
|
|
|
|
|
|
| Unamortized discount |
|
|
|
|
|
|
|
100,000 |
|
|
|
|
|
|
|
| Term A Loan | Secured promissory notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of debt |
|
|
|
|
|
|
|
5,000,000 |
|
|
|
|
|
|
|
| Term B Loan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum borrowing capacity |
|
|
|
|
15,000,000 |
|
|
|
|
|
|
|
|
|
|
| Remaining borrowing capacity |
|
|
|
|
$ 15,000,000 |
|
|
|
|
|
|
|
|
|
|
| Interest rate (as a percent) |
|
|
|
|
6.40% |
|
|
|
|
|
|
|
|
|
|
| Reference rate |
|
|
|
|
three month LIBOR |
|
|
|
|
|
|
|
|
|
|
| Number of business days prior to funding of new term loan |
|
|
|
|
3 days |
|
|
|
|
|
|
|
|
|
|
| Interest rate margin (as a percent) |
|
|
|
|
6.17% |
|
|
|
|
|
|
|
|
|
|